

Miren GarcÃ-a Cortes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7377368/publications.pdf>

Version: 2024-02-01

37
papers

2,154
citations

393982

19
h-index

276539

41
g-index

45
all docs

45
docs citations

45
times ranked

1811
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. <i>Hepatology</i> , 2006, 44, 1581-1588.	3.6	267
2	Phenotypic characterization of idiosyncratic drug-induced liver injury: The influence of age and sex. <i>Hepatology</i> , 2009, 49, 2001-2009.	3.6	266
3	Causality assessment methods in drug induced liver injury: Strengths and weaknesses. <i>Journal of Hepatology</i> , 2011, 55, 683-691.	1.8	164
4	Evaluation of Naranjo Adverse Drug Reactions Probability Scale in causality assessment of drug-induced liver injury. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 780-789.	1.9	150
5	HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. <i>Hepatology</i> , 2004, 39, 1603-1612.	3.6	134
6	Drug induced liver injury: an update. <i>Archives of Toxicology</i> , 2020, 94, 3381-3407.	1.9	125
7	Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. <i>Journal of Hepatology</i> , 2016, 65, 532-542.	1.8	115
8	Hepatotoxicity by Dietary Supplements: A Tabular Listing and Clinical Characteristics. <i>International Journal of Molecular Sciences</i> , 2016, 17, 537.	1.8	114
9	Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 116-125.	1.9	95
10	Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1495-1502.	2.4	83
11	Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry. <i>Journal of Hepatology</i> , 2021, 75, 86-97.	1.8	72
12	Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). Guía de práctica clínica. <i>Gastroenterología Y Hepatología</i> , 2018, 41, 328-349.	0.2	71
13	Assessment of drug-induced liver injury in clinical practice. <i>Fundamental and Clinical Pharmacology</i> , 2008, 22, 141-158.	1.0	66
14	The value of serum aspartate aminotransferase and gamma-glutamyl transpeptidase as biomarkers in hepatotoxicity. <i>Liver International</i> , 2015, 35, 2474-2482.	1.9	47
15	Cholestatic hepatitis related to use of irbesartan: a case report and a literature review of angiotensin II antagonist-associated hepatotoxicity. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 887-890.	0.8	45
16	Drug-induced liver injury in older people. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 862-874.	3.7	42
17	Hepatic Damage by Natural Remedies. <i>Seminars in Liver Disease</i> , 2018, 38, 021-040.	1.8	33
18	Drug-induced liver injury: a safety review. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 795-804.	1.0	31

#	ARTICLE	IF	CITATIONS
19	Liver injury after methylprednisolone pulses: A disputable cause of hepatotoxicity. A case series and literature review. <i>United European Gastroenterology Journal</i> , 2019, 7, 825-837.	1.6	29
20	Microbiota diversity in nonalcoholic fatty liver disease and in drug-induced liver injury. <i>Pharmacological Research</i> , 2022, 182, 106348.	3.1	29
21	Herbal and Dietary Supplements-Induced Liver Injury in Latin America: Experience From the LATINDILI Network. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e548-e563.	2.4	21
22	Is the Naranjo Probability Scale Accurate Enough to Ascertain Causality in Drug-Induced Hepatotoxicity?. <i>Annals of Pharmacotherapy</i> , 2004, 38, 1540-1541.	0.9	19
23	Clinical Characteristics and Outcome of Drug-Induced Liver Injury in the Older Patients: From the Young-Old to the Oldest-Old. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1147-1158.	2.3	16
24	Lymphocyte Profile and Immune Checkpoint Expression in Drug-Induced Liver Injury: An Immunophenotyping Study. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1604-1612.	2.3	15
25	Enfermedad hepática por alcohol. Guías de práctica clínica. Documento de consenso auspiciado por la AEEH. <i>Gastroenterología Y Hepatología</i> , 2019, 42, 657-676.	0.2	12
26	Incidence and prevalence of acute hepatitis E virus infection in patients with suspected Drug-Induced Liver Injury in the Spanish DILI Registry. <i>Liver International</i> , 2020, 41, 1523-1531.	1.9	10
27	Drug-Induced Liver Injury After Liver Transplantation. <i>Liver Transplantation</i> , 2020, 26, 1167-1176.	1.3	10
28	Acute leukemia after infliximab therapy. <i>American Journal of Gastroenterology</i> , 2003, 98, 2577.	0.2	7
29	Lansoprazole-Induced Hepatic Dysfunction. <i>Annals of Pharmacotherapy</i> , 2003, 37, 1731-1731.	0.9	6
30	Safety of treating acute liver injury and failure. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 191-203.	1.0	6
31	Outbreak of acute hepatitis A in the health area served by the Hospital Universitario Virgen de la Victoria (HUVV): a change in epidemiology. <i>Revista Espanola De Enfermedades Digestivas</i> , 2018, 110, 380-385.	0.1	6
32	Differential iNKT and T Cells Activation in Non-Alcoholic Fatty Liver Disease and Drug-Induced Liver Injury. <i>Biomedicines</i> , 2022, 10, 55.	1.4	4
33	Unusual duodenal duplication cyst associated with partial gastric diverticulum in a middle-aged woman: are they congenital or acquired?. <i>Digestive Diseases and Sciences</i> , 2002, 47, 304-308.	1.1	3
34	Killer Immunoglobulin-Like Receptor Profiles Are not Associated with Risk of Amoxicillin-Clavulanate-Induced Liver Injury in Spanish Patients. <i>Frontiers in Pharmacology</i> , 2016, 7, 280.	1.6	3
35	Management of Pharmacologic Adverse Effects in Advanced Liver Disease. <i>Clinical Drug Investigation</i> , 2022, 42, 33-38.	1.1	3
36	Causality Assessment. , 2013, , 287-302.		1

#	ARTICLE	IF	CITATIONS
37	¿Debemos seguir usando un inhibidor de la bomba de protones en pacientes con cardiopatía isquémica y doble antiagregación plaquetaria?. <i>Cardiocyte</i> , 2010, 45, 79-82.	0.0	0